Tools
Tools
Tsampasian, Vasiliki, Elghazaly, Hussein, Chattopadhyay, Rahul Kumar, Ali, Omar, Corballis, Natasha, Chousou, Panagiota Anna, Clark, Allan 
ORCID: https://orcid.org/0000-0003-2965-8941, Garg, Pankaj ORCID: https://orcid.org/0000-0002-5483-169X and Vassiliou, Vassilios ORCID: https://orcid.org/0000-0002-4005-7752
(2022)
Sodium glucose co-transporter 2 (SGLT2) inhibitors in heart failure with preserved ejection fraction: A systematic review and meta-analysis.
European Journal of Preventive Cardiology, 29 (6).
e227–e229.
ISSN 2047-4873
Preview |
PDF (F1. CV death or HHF)
- Accepted Version
Download (291kB) | Preview |
Preview |
PDF (Accepted_Manuscript)
- Accepted Version
Download (172kB) | Preview |
Preview |
PDF (SupplMaterial_Updated)
- Accepted Version
Download (513kB) | Preview |
![[thumbnail of Table_updated]](https://ueaeprints.uea.ac.uk/style/images/fileicons/other.png) |
Microsoft Word (OpenXML) (Table_updated)
- Accepted Version
Download (15kB) |
Abstract
Whilst heart failure with preserved ejection fraction (HFpEF) is increasingly studied, the search for a single pharmacotherapeutic agent that will improve hard endpoints like hospitalization and mortality still continues.1 Given the various subphenotypes of HFpEF,2 this makes it difficult for a single agent to be universally beneficial. The recent publication of EMPEROR-PRESEVED3 was an instrumental time for an updated meta-analysis focused on sodium glucose co-transporter 2 inhibitors (SGLT2i) use in HFpEF.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | epidemiology,cardiology and cardiovascular medicine ,/dk/atira/pure/subjectarea/asjc/2700/2713 |
| Faculty \ School: | Faculty of Medicine and Health Sciences > Norwich Medical School |
| Related URLs: | |
| Depositing User: | LivePure Connector |
| Date Deposited: | 28 Oct 2021 00:49 |
| Last Modified: | 19 May 2023 09:38 |
| URI: | https://ueaeprints.uea.ac.uk/id/eprint/81902 |
| DOI: | 10.1093/eurjpc/zwab189 |
Actions (login required)
 |
View Item |